Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells

Cancer Science

Volumn 107, Issue 2, 2016, Pages 140-148

  Naka, Kazuhito ^a,b   Ishihara, Kaori ^a   Jomen, Yoshie ^a   Jin, Cheng Hua ^c   Kim, Dong Hyun ^d   Gu, Yoon Kang ^d   Jeong, Eun Sook ^d   Li, Shaoguang ^e   Krause, Daniela S ^f   Kim, Dong Wook ^g   Bae, Eunjin ^a,h   Takihara, Yoshihiro ^b   Hirao, Atsushi ^a   Oshima, Hiroko ^a   Oshima, Masanobu ^a   Ooshima, Akira ^h   Sheen, Yhun Yhong ^c   Kim, Seong Jin ^h   Kim, Dae Kee ^c  

^a KANAZAWA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Ewha Womans University   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f GOETHE UNIVERSITY   (Germany)

^g The Catholic University of Korea   (South Korea)

^h CHA University   (South Korea)

Author keywords

ALK5 inhibitor; CML stem cells; Relapse prevention; TGF signaling; TKI resistance

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; DASATINIB; EW 7197; IMATINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA SIGNALING INHIBITOR; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; IMIDAZOLE DERIVATIVE; N-((4-((1,2,4)TRIAZOLO(1,5-A)PYRIDIN-6-YL)-5-(6-METHYLPYRIDIN-2-YL)-1H-IMIDAZOL-2-YL)METHYL)-2-FLUOROANILINE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIDAZINE DERIVATIVE; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW DERIVED MONONUCLEAR CELL; CANCER SURVIVAL; CELL SELF-RENEWAL; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMIA INITIATING CELL; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SPLENOMEGALY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; GENETIC TRANSFECTION; PATHOLOGY;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED C57BL; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIDAZINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TRIAZOLES;

EID: 84958923762     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12849     Document Type: Article

References (32)

1. Naka K, Hoshii T, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci 2010; 101: 1577-81.
2. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012; 12: 513-26.
3. Mahon FX, Rea D, Guilhot J et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-35.
4. Bhatia R, Holtz M, Niu N et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-7.
5. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17.
6. Hochhaus A, O'Brien SG, Guilhot F et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-61.
7. Giles FJ, Rosti G, Beris P et al. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Rev Hematol 2010; 3: 665-73.
8. Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-70.
9. Ross DM, Branford S, Seymour JF et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010; 24: 1719-24.
10. Ibrahim AR, Eliasson L, Apperley JF et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011; 117: 3733-6.
11. Sinclair A, Latif AL, Holyoake TL. Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol 2013; 169: 1693-707.
12. Ahmed W, Van Etten RA. Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program 2013; 2013: 189-200.
13. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.
14. O'Hare T, Shakespeare WC, Zhu X et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401-12.
15. Khorashad JS, Kelley TW, Szankasi P et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 2013; 121: 489-98.
16. Blank U, Karlsson S. TGF-β signaling in the control of hematopoietic stem cells. Blood 2015; 125: 3542-50.
17. Yamazaki S, Ema H, Karlsson G et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 2011; 147: 1146-58.
18. Naka K, Hoshii T, Muraguchi T et al. TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-80.
19. Krause DS, Fulzele K, Catic A et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med 2013; 19: 1513-17.
20. Jin CH, Krishnaiah M, Sreenu D et al. Discovery of N-((4-([1, 2, 4]Triazolo[1, 5-α]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2- fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type 1 receptor kinase as cancer immunotherapeutic/antifibrotic agent. J Med Chem 2014; 57: 4213-38.
21. Yoon JH, Jung SM, Park SH et al. Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes. EMBO Mol Med 2013; 5: 1720-39.
22. Son JY, Park S-Y, Kim S-J et al. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis. Mol Cancer Ther 2014; 13: 1704-16.
23. Koschmieder S, Gottgens B, Zhang P et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 2005; 105: 324-34.
24. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24: 57-60.
25. Reynaud D, Pietras E, Barry-Holson K et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 2011; 20: 661-73.
26. Pellicano F, Scott MT, Helgason GV et al. The anti-proliferative activity of kinase inhibitors in chronic myeloid leukaemia cells is mediated by FOXO transcription factors. Stem Cells 2014; 32: 2324-37.
27. Naka K, Jomen Y, Ishihara K et al. Dipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells. Nat Commun 2015; 6: 8039. doi: 10.1038/ncomms9039.
28. Peng C, Brain J, Hu Y et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 2007; 110: 678-85.
29. Corbin AS, Agarwal A, Loriaux M et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396-409.
30. Hamilton A, Helgason GV, Schemionek M et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012; 119: 1501-10.
31. Ma L, Shan Y, Bai R et al. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med 2014; 6: 252ra121.
32. Møller GM, Frost V, Melo JV, Chantry A. Upregulation of the TGFβ signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia. FEBS Lett 2007; 581: 1329-34.